Happy Masks

Learn more about Monoclonal Antibody Treatment (mAbs)

Read our FAQs to understand how monoclonal antibody treatment works, and why it's a treatment that may benefit you or a loved one if you've recently tested positive for COVID-19. Early treatment is key. 

I’m a paragraph. Double click here or click Edit Text to add some text of your own or to change the font. This is the place for you to tell your site visitors a little bit about you and your services.


Frequently asked questions

What are Monoclonal Antibodies?

Monoclonal antibodies are lab-produced antibodies that are manufactured to mimic natural antibodies.Monoclonal antibodies for COVID-19 may block the virus that causes COVID-19 from attaching to human cells, making it more difficult for the virus to cause further harm. In the US, Eli Lilly & Regeneron manufactured drugs are infused in hospital/healthcare center settings in the early stages of COVID-19 for those who qualify.

How can I access Monoclonal Antibody Treatment?

Monoclonal antibodies are administered in hospitals/medical centers as an outpatient treatment. A patient may need their doctor’s approval before making an appointment for monoclonal treatment but those vary from one specific treatment center to the next. Since each hospital has its own procedure to gain access to this treatment, we strongly encourage patients to call our 24/7 hotline at 828-4-plasma to assist in finding the best way to access the therapy.

Is Monoclonal Antibody Treatment the same thing as convalescent plasma therapy?

No, monoclonal antibodies are the synthetic antibodies given to early-stage COVID positive patients as an outpatient treatment. Convalescent plasma therapy uses the plasma (liquid portion of the blood) containing antibodies from recovered COVID-19 patients. Convalescent plasma therapy is currently used as inpatient treatment for hospitalized COVID-19 patients only at a more serious stage of their illness.

Who is eligible for Monoclonal Antibody Treatment?

In the US, the FDA has authorized under the EAU the use of monoclonal antibodies for COVID-19 positive patients who are considered high risk. A partial list of FDA approved high-risk criteria to qualify for the treatment is BMI greater than 35, chronic kidney disease, diabetic, immunosuppressive disease, immunosuppressive treatment; patients who are 55 years old and older who also have cardiovascular disease, hypertension, or chronic respiratory disease; patients who are 65 years and older; adolescents 12-17 with BMI greater than 85th percentile. Our hotline staff is equipped to help you determine if you can access this treatment based on your age, weight, and medical conditions.

What happens during the treatment process?

The monoclonal antibodies are delivered into a patient’s vein via intravenous (IV) infusion. The average time of a Monoclonal Antibody Treatment is approximately 17 min-1 hour and then an hour for observation. If administered in an ER, we advise allocating extra time for waiting.

How can I find a monoclonal antibody treatment provider near me?

You can access the list of providers from our directory https://www.covidplasmasavealife.com/copy-of-monoclonal-antibody-covid-1 or call our 24/7 hotline at 828-4-plasma to have a CPI hotline volunteer assist you in finding the closest provider of monoclonal antibodies.

Does insurance cover Monoclonal Antibody Treatment?

Yes, the treatment is covered by the USA government although some facilities may charge for administrative fees. Each patient should be aware of their own plan’s coverage.